sellWeak cluster of 3
Thomas Gad sold $64k of YMAB
CHIEF BUSINESS OFFICER at Y-mAbs Therapeutics, Inc.. 3,900 shares at an average of $16.44, traded Mar 5, 2024, filed Mar 7, 2024.
Warning score
38Value
$64k
3,900 shares
Holdings after
158,700
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +8Trade size$64k at market
- 0Share of holdings soldSold 2.4% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-031941, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2024 | SOpen-market sale Common Stock | -3,900 | $16.44 | $64k | 158,700 | Mar 7, 2024 |
Related signals
Other insiders at Y-mAbs Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $57k 10,810 shares | -5% | |
| 40Moderate | Y-mAbs Therapeutics, Inc. | Gerard Ber director | $8,664 722 shares | -31% | |
| 63Notable | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $841k 70,000 shares | -30% | |
| 53Moderate | Y-mAbs Therapeutics, Inc. | Bo Kruse EVP, CFO, SECRY & TREAS. | $723k 60,000 shares | -25% | |
| 44Moderate | Y-mAbs Therapeutics, Inc. | Thomas Gad CHIEF BUSINESS OFFICER | $396k 32,351 shares | -12% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Vignesh Rajah SVP & CHIEF MEDICAL OFFICER | $28k 1,711 shares | -5% | |
| 35Weak | Y-mAbs Therapeutics, Inc. | Susan Laura Smith SVP & CHIEF COMMERCIAL OFFICER | $28k 1,682 shares | -5% | |
| 50Moderate | YMABsell Y-mAbs Therapeutics, Inc. | Thomas Gad Chief Business Officer | $1.0M 150,000 shares | -36% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Biotech ApS WG director | $44k 6,455 shares | +0% | |
| 29Weak | Y-mAbs Therapeutics, Inc. | Johan Wedell-Wedellsborg director | $44k 6,455 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.